Igyxos’ IGX12 brings a fresh approach to infertility treatment, aiming to improve outcomes for both men and women.

Delve into Vandria's technology and its Alzheimer's candidate, VNA-318, the first mitophagy-based candidate in Alzheimer's in ...

While non-exhaustive, this list offers an overview of the year’s biotech events taking place around the world, aimed at partnering and connecting with decision makers in biopharma. If there is a ...

Research Triangle Park in North Carolina has emerged as one of the U.S’s most dynamic and rapidly expanding biotech hubs, home to a thriving ecosystem of established pharma companies, research ...

A new wave of metabolic disease drugs beyond GLP-1 agonists is emerging to address the unmet needs of patients.

Discover six obesity deals made so far in 2025, with dealmaking activity in the field being largely dominated by big pharma companies.

Discover the emergence of dual-payload ADCs and PDCs, which could mark a significant evolution in targeted therapeutics.

Since the first biosimilar approval in Europe twenty years ago, biosimilars have provided 6.9 billion patient treatment days and now provide 12% of the total volume of biologic treatments in Europe.

Mapping how T-cell leukemia develops, a team of researchers at the Wellcome Sanger Institute, Great Ormond Street Hospital, University College London, and Addenbrooke’s Hospital in the U.K. identified ...

Last week nearly 6000 people from more than 3200 companies gathered in Vienna for the annual BIO-Europe partnering conference. Over three days, more than 32,000 meetings were facilitated between ...

If you thought September was huge for M&As in the biopharma space, you didn’t see October coming. Nine major M&As were signed, with most of them being multi-billion-dollar deals in various therapeutic ...